That's a great question! MIMRYLO™ (rusfertide) is indeed generating buzz in the PV community. It's a newer treatment that works by mimicking a hormone called hepcidin, which helps regulate iron levels in the body. By limiting iron availability, it can help control red blood cell production in people with PV.
The FDA Show Full Answer
That's a great question! MIMRYLO™ (rusfertide) is indeed generating buzz in the PV community. It's a newer treatment that works by mimicking a hormone called hepcidin, which helps regulate iron levels in the body. By limiting iron availability, it can help control red blood cell production in people with PV.
The FDA approval is exciting news, as it gives people with PV another option to help manage their condition, particularly for those who rely heavily on phlebotomy (regular blood withdrawals).
Here are a few key things worth knowing:
- It targets iron regulation rather than directly suppressing bone marrow activity
- It may help reduce the need for frequent phlebotomies
- As with any new treatment, it's important to discuss with your hematologist whether it's the right fit for your specific situation
- Your doctor will consider your full treatment history before recommending any changes
This is definitely worth bringing up at your next appointment! Your hematologist will be the best person to walk you through whether MIMRYLO™ could be a good option for you personally.
August 29
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
